All Articles

Tejon Ranch flipped a loss into a $2.6M profit by cutting costs and doubling down on industrial real estate. But is this disciplined focus enough to fund its massive future?

Levelwear's new NFL deal completes its sports empire. But its true goal may be to change how we wear our loyalty, one premium, lifestyle garment at a time.

A stunning quarter for Establishment Labs shows a company moving from high-growth potential to high-growth reality, underpinned by strategic discipline.

The 2026 Pet Innovation Awards highlight a market in transformation. It’s no longer just about food and toys, but a tech-driven wellness ecosystem.

Australia's top online bookmaker is betting that the key to AI leadership isn't just speed, but control. Its new AI Gateway aims to solve the core challenge of scaling AI in a high-stakes, real-time world.

Shueisha's free MANGA MILLION platform is a centennial celebration, but a closer look reveals a strategic pivot with major questions about AI and creative labor.

The media giant posts a second straight profitable quarter, but a closer look reveals a strategy built on deep cuts and a shrinking user base.

Global tech firm Meta IT rebrands as Insi, targeting North America’s crowded AI and digital market with a unique philosophy-driven approach. Can it succeed?

As AI both strains and supports the energy grid, EPRI's SAFERai.power initiative unites rivals and regulators to build a common framework for safe deployment.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

With its acquisition of PingCx, Facility Grid is betting on an AI-powered, unified platform to end building performance decay and reshape the ConTech market.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

With a new CEO, fresh funding, and a key partnership with Intellia, ReCode Therapeutics is launching a two-pronged assault on cystic fibrosis.

MetLife's fifth 'Pet Insurance of the Year' award isn't just a trophy. It's a signal of a massive cultural and economic shift in how we care for our pets.

Dolby's new Dolby Vision 2, launching first on Hisense TVs, isn't just another spec bump. It's an intelligent system designed to restore artistic intent and adapt to your life.

A $25k grant from a tech company to a biotech startup reveals a powerful new model for industrial transformation, targeting the hidden plastic in our food system.

Amphenol's stock split and dividend aren't just financial housekeeping. They're a bold signal of confidence in the booming tech hardware market. Here's why.

A new line of matcha products reveals more than just new flavors; it's a blueprint for how consumer goods giants are winning the battle for the kitchen counter.